International journal of nanomedicine · 2025
Pleiotropic Multi-Drug Co-Assembled Nanocomposites Offer Protection Against Doxorubicin-Induced Cardiotoxicity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Dan, Li Can, Li Jiajin, Zeng Jieying, Jia Mengjie, Yuan Wenjing, Liu Lingjuan, Tang Yi, Wang Yi, Tian Jie
Аннотация
BACKGROUND: Doxorubicin (DOX) is a first-line chemotherapeutic agent, yet its clinical utility is limited by doxorubicin-induced cardiotoxicity (DIC), a dose-dependent side effect. Current drug delivery strategies fail to prevent off-target accumulation of DOX in cardiac tissue, necessitating innovative therapeutic approaches that protect the heart without compromising antitumor efficacy through targeted cardioprotection.
METHODS: We developed a multifunctional self-assembled nanoplatform (PGPP/NPs) via co-assembly of ginsenoside Rb1, probucol (PB), and a phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor (PI), with surface modification using PCM peptide for cardiomyocyte-targeted delivery. In vitro and in vivo models of DIC were used to evaluate targeting specificity and therapeutic efficacy. Mechanistic investigations included ROS detection (DCFH-DA assay), inflammatory phenotype analysis (immunohistochemistry for CD68 and CD206), and autophagy flux assessment (immunofluorescence for LC3-II).
RESULTS: PGPP/NPs demonstrated selective accumulation in cardiomyocytes compared to non-targeted GPP/NPs (p<0.05). This nanocomposite significantly alleviated DIC through antioxidative, anti-inflammatory, and autophagy-promoting mechanisms. Notably, it reduced DIC severity while preserving the antitumor efficacy of DOX.
CONCLUSION: This novel therapeutic strategy shows great promise for mitigating chemotherapy-induced cardiotoxicity and may be extended to other chemotherapeutic agents with cardiac side effects.
METHODS: We developed a multifunctional self-assembled nanoplatform (PGPP/NPs) via co-assembly of ginsenoside Rb1, probucol (PB), and a phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor (PI), with surface modification using PCM peptide for cardiomyocyte-targeted delivery. In vitro and in vivo models of DIC were used to evaluate targeting specificity and therapeutic efficacy. Mechanistic investigations included ROS detection (DCFH-DA assay), inflammatory phenotype analysis (immunohistochemistry for CD68 and CD206), and autophagy flux assessment (immunofluorescence for LC3-II).
RESULTS: PGPP/NPs demonstrated selective accumulation in cardiomyocytes compared to non-targeted GPP/NPs (p<0.05). This nanocomposite significantly alleviated DIC through antioxidative, anti-inflammatory, and autophagy-promoting mechanisms. Notably, it reduced DIC severity while preserving the antitumor efficacy of DOX.
CONCLUSION: This novel therapeutic strategy shows great promise for mitigating chemotherapy-induced cardiotoxicity and may be extended to other chemotherapeutic agents with cardiac side effects.